January 2015
Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy?
Mohammed Eslam, Jacob George Pages 5-8
How to achieve immune control in chronic hepatitis B?
Margo J. H. van Campenhout, Harry L. A. Janssen Pages 9-16
Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection
Huei-Ru Cheng, Jia-Horng Kao, Hui-Lin Wu, Tai-Chung Tseng… Pages 35-42
Reimbursement policies in the Asia-Pacific for chronic hepatitis B
Seng Gee Lim, Deepak N. Amarapurkar, Henry Lik-Yuen Chan… Pages 43-51
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome
A comparative study of patients’ knowledge about hepatitis C in the United States and in urban and rural China
Elizabeth Wu, Xisui Chen, Zhe Guan, Claudia Cao, Huiying Rao… Pages 58-66
Prognostic effect of response to interferon therapy after laparoscopic splenectomy among patients with marked thrombocytopenia and hepatitis C virus-related cirrhosis
Hideyuki Tamai, Yoshiyuki Mori, Naoki Shingaki, Ryo Shimizu… Pages 67-75
High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation
Nabiha Faisal, Khalid Mumtaz, Max Marquez, Eberhard L. Renner… Pages 76-83
April 2015
Sofosbuvir for treatment of chronic hepatitis C
Sarah Kattakuzhy, Rachel Levy, Shyam Kottilil Pages 161-173
Management of post transplant hepatitis C in the direct antiviral agents era
Audrey Coilly, Bruno Roche, Jean-Charles Duclos-Vallée… Pages 192-201
Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients
Charlie Laohapand, Emvalee Arromdee, Tawesak Tanwandee Pages 202-208
High rate of core promoter and precore mutations in patients with chronic hepatitis B
Sumbella F. Baqai, James Proudfoot, Debbie H. Yi… Pages 209-217
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy
Edith Y. Ho, Thomas Yau, Franck Rousseau, E. Jenny Heathcote… Pages 224-230
Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection
Ching-Sheng Hsu, Wei-Liang Liu, You-Chen Chao… Pages 231-242
Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
Maria Buti, Scott Fung, Edward Gane, Nezam H. Afdhal… Pages 243-250
Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians
Susanne Knapp, Zainab Zakaria, Mohamed Hashem, Hassan Zaghla…
July 2015
Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure
Man-Fung Yuen Pages 373-377
A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan
Heather Bennett, Nathalie Waser, Karissa Johnston… Pages 378-390
Acute kidney injury in hepatitis B-related acute-on-chronic liver failure without preexisting liver cirrhosis
Zuxiong Huang, Chun Lin, Jiankai Fang, Ning Wang, Rui Zhou… Pages 416-423
HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b
Yosuke Hirotsu, Tatsuo Kanda, Hiroshi Matsumura… Pages 424-430
Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients
Pardha Devaki, David Jencks, Brittany E. Yee, Mindie H. Nguyen Pages 431-437
October 2015
Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries
Masao Omata, Tatsuo Kanda, Osamu Yokosuka, Darrell Crawford… Pages 486-507
Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis
Hong Peng, Fang Wei, Jun-Ying Liu, Huai-Dong Hu, Hong Ren… Pages 543-557
Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test
Xueying Xu, Yang Su, Ruixiang Song, Yang Sheng, Wensi Ai… Pages 558-566
Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis
Myron John Tong, Thatcher Thi Huynh, Surachate Siripongsakun… Pages 567-577
Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1–5 years with iatrogenic chronic hepatitis C
Shi-Shu Zhu, Qing-Lei Zeng, Yi Dong, Zhi-Qiang Xu, Li-Min Wang… Pages 578-585
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies
Alessia Piluso, Laura Gragnani, Elisa Fognani, Elena Grandini… Pages 586-593
January 2016
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
K. Sarin, M. Kumar, G. K. Lau, Z. Abbas, H. L. Y. Chan… Pages 1-98
Looking into the crystal ball: biomarkers for outcomes of HBV infection
Hung-Chih Yang, Jia-Horng Kao Pages 99-101
Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy
Man-Fung Yuen Pages 102-105
Late liver function test abnormalities post-adult liver transplantation: a review of the etiology, investigation, and management
Oscar Mitchell, Arif M. Cosar, Mohammad U. Malik, Ahmet Gurakar Pages 106-114
Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection
Li Wang, Zhi-Qiang Zou, Kai Wang, Ji-Guang Yu, Xiang-Zhong Liu Pages 133-138
Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014
Arpan Patel, Suna Yapali, Anna S. F. Lok Pages 139-146
Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus
Wen-Chun Liu, Chih-Peng Lin, Chun-Pei Cheng, Cheng-Hsun Ho… Pages 147-157
March 2016
Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense
Yuanyuan Kong, Hong You, Jidong Jia Pages 239-241
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
Sheng-Shun Yang, Jia-Horng KaoPages 258-266
Advances in therapeutics for chronic hepatitis B
Ninghan Yang, Antonio BertolettiPages 277-285
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
Chia-Chi Wang, Chih-Lin Lin, Tsai-Yuan Hsieh, Kuo-Chih Tseng… Pages 294-301
Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment
Dorota Kozielewicz, Waldemar Halota, Magdalena Wietlicka-Piszcz Pages 302-309
High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study
Tess Petersen, Kerry Townsend, Lori A. Gordon…Pages 310-319
Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients
Takao Watanabe, Yoshio Tokumoto, Kouji Joko, Kojiro Michitaka…Pages 320-327
May 2016
https://link.springer.com/journal/12072/10/3
Prevention and management of hepatitis B virus reactivation in cancer patients
Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, Man-Fung YuenPages 407-414
Hepatitis C virus as a systemic disease: reaching beyond the liver
Kirat Gill, Hasmik Ghazinian, Richard Manch, Robert GishPages 415-423
Advances in the management of HIV/HCV coinfection
Mattias Mandorfer, Philipp Schwabl, Sebastian Steiner…Pages 424-435
The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure
Wan Yue-Meng, Li-Hong Yang, Jin-Hui Yang, Ying Xu, Jing Yang…Pages 462-469
Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008–2010 Korea National Health and Nutrition Examination Surveys
Myong Ki Baeg, Seung Kew Yoon, Sun-Hye Ko, Kyung-Do Han…Pages 470-477
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis
Edward J. Gane, Régine Rouzier, Tarek Hassanein…Pages 478-487
July 2016
iNKT cells in chronic HBV: a balancing act
Maike Hofmann, Robert ThimmePages 535-537
HBV culture and infectious systems
Nelson Hayes, Kazuaki ChayamaPages 559-566
Hepatitis B virus receptors and molecular drug targets
Eloi R. Verrier, Che C. Colpitts, Camille Sureau…Pages 567-573
Prevention of hepatitis B virus-associated liver diseases by antiviral therapy
Akinobu Tawada, Tatsuo Kanda, Fumio Imazeki, Osamu YokosukaPages 574-593
The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection
Man Li, Zhen-Hua Zhou, Xue-Hua Sun, Xin Zhang, Xiao-Jun Zhu…Pages 594-601
Will a second biopsy sample affect treatment decisions in patients with chronic hepatitis B?
Fuat Ekiz, İlhami Yuksel, Ata Turker Arikök, Baris Yilmaz…Pages 602-605
Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis
Xueyuan Nian, Zhihui Xu, Yan Liu, Jianhong Chen, Xiaodong Li…Pages 606-615
Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry
Marina Roytman, Resham Ramkissoon, Christina Wu, Leena Hong…Pages 616-623
Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment
Karla Thornton, Paulina Deming, Richard A. Manch, Ann Moore…Pages 624-631
September 2016
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
Masao Omata, Tatsuo Kanda, Lai Wei, Ming-Lung Yu…Pages 681-701
APASL consensus statements and recommendation on treatment of hepatitis C
Masao Omata, Tatsuo Kanda, Lai Wei, Ming-Lung Yu…Pages 702-726
HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy
Geoffrey Dusheiko, Bo Wang, Ivana CareyPages 727-729
Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals
Che C. Colpitts, Thomas F. BaumertPages 741-748
Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review
Dinesh Jothimani, Sanjay Govil, Mohamed RelaPages 749-761
Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure
Fabien Zoulim, Jolanta Białkowska-Warzecha…Pages 779-788
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
Dong Ji, Guo-Feng Chen, Cheng Wang, Yu-Dong Wang, Qing Shao…Pages 789-798
HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes
Tien Huey Lim, Edward Gane, Chris Moyes, Barry Borman…Pages 829-837
November 2016
Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia
Qiuju Tian, Jidong JiaPages 854-860
Hepatitis C genotype 3 disease
Sarah Kattakuzhy, Rachel Levy, Elana Rosenthal, Lydia Tang… Pages 861-870
Functionally aberrant dendritic cell subsets and expression of DC-SIGN differentiate acute from chronic HBV infection
Sukriti Sukriti, Nirupma Trehanpati, Manoj Kumar… Pages 916-923
Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China
Weixia Ke, Chi Zhang, Li Liu, Yanhui Gao, Zhenjiang Yao… Pages 924-936
Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis
Shikha Shrivastava, Eric G. Meissner, Emily Funk, Seerat Poonia… Pages 937-946
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus
Young-Suk Lim, Sang Hoon Ahn, Kwan Sik Lee, Seung Woon Paik…Pages 947-955
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy
Hiroko Nagata, Mina Nakagawa, Yuki Nishimura-Sakurai, Yu Asano…Pages 956-964
Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India
Aracely Tamayo, Samir R. Shah, Shobna Bhatia, Abhijit Chowdhury…
Jan 2017
Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace
Interferon-free treatment for HCV-infected patients with decompensated cirrhosis
Molecular mechanisms of HBeAg in persistent HBV infection
Li-Min Chen, Xue-Gong Fan, Jing Ma, Bo He, Yong-Fang Jiang
HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea
Chung Hwan Jun, Ban Suk Kim, Chan Young Oak, Du Hyeon Lee
Hepatitis B virus infection in children of HBV-related chronic liver disease patients: a study of intra-familial HBV transmission
Hartono Gunardi, Melanie Y. Iskandar, Turyadi, Susan I. Ie
March 2017
Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
Chandana Papudesu, Shyamasundaran Kottilil, Shashwatee Ba
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy
Rebecca Lee, Shyam Kottilil, Eleanor Wilson
Virus-induced hepatocellular carcinoma with special emphasis on HBV
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
Mark S. Sulkowski, Walford J. Fessel, Adriano Lazzarin…
May 2017
HCV management in resource-constrained countries
Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis
Mi Young Jeon, Hye Won Lee, Seung Up Kim, Ja Yoon Heo
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study
Sandeep Singh Sidhu, Nirmaljeet Singh Malhi, Omesh Goya
A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C
July 2017
Current progress in host innate and adaptive immunity against hepatitis C virus infection
Jijing Shi, Yuanyuan Li, Wenxian Chang, Xuexiu Zhang…
Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects
Yanhua Ding, Hong Zhang, Xiaojiao Li, Cuiyun Li, Guiling Chen
Noninvasive serum models to predict significant liver related events in chronic hepatitis C
Ragesh Babu Thandassery, Saad Al Kaabi, Madiha E. Soofi…
September 2017
Functional restoration of CD56bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B
Tao Chen, Lin Zhu, Aichao Shi, Lin Ding, Xiaoping Zhang
Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis
Zilin Tang, Xiaodong Li, Shunquan Wu, Yan Liu, Yan Qiao…
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant
Mohamed Shoreibah, Jordan Orr, DeAnn Jones, Jie Zhang
A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry
Catherine Fauvelle, Melanie Lambotin, Laura Heydmann…
November 2017
Viral factors for HBV mother-to-child transmission
Mother-to-infant transmission of hepatitis B virus: challenges and perspectives
Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread
Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey
Necati Örmeci, Simten Malhan, İsmail Balık, Gül Ergör…
January 2018
Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?
Simon H. Bridge, Sabrina Pagano, Meleri Jones, Graham R. Foster
March 2018
Prevention of mother-to-child transmission: the key of hepatitis B virus elimination
The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection
Fan Li, Xiaodong Li, Tao Yan, Yan Liu, Yongqian Cheng…
Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B
Tianyu He, Yuqing Bai, Haodong Cai, Xiaojuan Ou, Min Liu
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
Lai Wei, Qing Xie, Jin Lin Hou, Hong Tang, Qin Ning, Jun Cheng…
Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment
Tomomi Okubo, Masanori Atsukawa, Akihito Tsubota…
High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy
Rasha Eletreby, Mohamed Said, Zeinab Abdellatif, Yasmin Saad
Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation
Tomoki Ryu, Yuko Takami, Yoshiyuki Wada, Masaki Tateishi…
May 2018
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy
Ameer Abutaleb, Shyam Kottilil, Eleanor Wilson
Platelets’ increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis
Lin Wang, Bingqiong Wang, Hong You, Xiaoning Wu, Jialing Zhou…
Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan
Fumitaka Suzuki, Naoya Hatanaka, Etsuya Bando, Koji Nakamura
July 2018
Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt
Tatsuo Kanda, Shunichi Matsuoka, Mitsuhiko Moriyama
Depression, fatigue and neurocognitive deficits in chronic hepatitis C
Sern Wei Yeoh, Alex C. N. Holmes, Michael M. Saling…
Global HBV burden: guesstimates and facts
Dina Ginzberg, Robert J. Wong, Robert GishPages 315-329
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis
Seogsong Jeong, Guijuan Luo, Zhi-Heng Wang, Meng Sha, Lei Chen…Pages 330-338
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
Shiha, R. Soliman, M. ElBasiony, A. A. Hassan… Pages 339-347
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabaar… Pages 348-355
Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
Namiki Izumi, Tetsuo Takehara, Kazuaki Chayama… Pages 356-367
September 2018
Fatty liver checkmates hepatitis B virus
Gayatri Ramakrishna, Nirupma Trehanpati Pages 387-389
Clinical implication and viral mutation in basal core promoter/pre-core of hepatitis B virus C/D recombinant
Hua Li, Qilu She, Yu Liu, Yuehe Ding, Shenghua Shi, Jijie Li… Pages 447-455
Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study
Ming-Wei Lai, Chao-Wei Hsu, Chih-Lang Lin, Rong-Nan Chien… Pages 456-464
Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China
Yuanyuan Li, Linghua Li, Jun Liu, Da-Wei Zhang, Fang Zhao… Pages 465-473
A changing paradigm: management and treatment of the HCV/HIV-co-infected patient
Ameer Abutaleb, Kenneth E. ShermanPages 500-509
Hepatitis B-positive health-care workers: why they should not switch to non-exposure-prone jobs
Ankur Jindal Pages 520-522